FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
|Articles|December 8, 2020
Guideline-directed Therapy for Asthma & COPD: Use This, Not That
Author(s)Veronica Hackethal, MD
Use ICS monotherapy for this, not that. For asthma COPD overlap, don't use that, use this. Try these 4 questions on GINA and GOLD recommended treatments.
Advertisement
Symptoms of asthma and COPD can sometimes overlap, complicating diagnosis and treatment. This quiz tests your knowledge of guideline-recommended issues surrounding treatment of asthma, COPD and asthma/COPD overlap, ie, when to use this, and not that.
Advertisement
Related to this article
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
2
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
Clinical Inertia and Poor Measurement Technique Undermine BP Control
5